oxonic acid has been researched along with Body Weight in 20 studies
Oxonic Acid: Antagonist of urate oxidase.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5 mg/kg/day regimen produced one dead or moribund dog of each sex; black-brown patch (melanin deposition) and inflammatory changes in the eyes and skin; decreased in body weight gains; increases in MCV, MCH, monocyte ratio, and serum protein and uric acid; decreases in lymphocyte ratio and erythrocyte count, hematocrit, hemoglobin, albumin, A/G ratio, cholesterol (esterified, total and free), phospholipids, triglycerides, cholinesterase activity and creatinine; increases in relative liver and adrenal weights." | 3.69 | [A 52-week oral toxicity study of a new antineoplastic agent S-1 in dogs]. ( Enomoto, M; Inoue, H; Kitajima, S; Kobayashi, K; Okamura, T; Watari, N; Yamaguchi, S, 1996) |
| " According to ADME (absorption, distribution, metabolism, and excretion) simulation in silico, flazin had good oral bioavailability in vivo." | 1.43 | Effect of Soy Sauce on Serum Uric Acid Levels in Hyperuricemic Rats and Identification of Flazin as a Potent Xanthine Oxidase Inhibitor. ( Li, H; Lin, L; Su, G; Wang, Y; Zhao, M, 2016) |
| " The mechanism by which uric acid reduces the bioavailability of intrarenal nitric oxide is not known." | 1.35 | Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. ( Avila-Casado, C; Franco, M; Johnson, RJ; Nakagawa, T; Rodríguez-Iturbe, B; Sánchez-Lozada, LG; Sautin, YY; Soto, V; Tapia, E, 2008) |
| " In the CDHP and Oxo treatment groups of rats, the only toxic signs were soft or diarrheal stools on the dosing day." | 1.29 | [Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo]. ( Hayashi, T; Hirota, T; Irimura, K; Ohmae, S; Tanaka, G, 1996) |
| " No adverse effects of S-1 on the length of gestation, gestation index, delivery and nursing ability were found." | 1.29 | [Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (IV)--Perinatal and postnatal study in rats by oral administration]. ( Fujimura, T; Furuhashi, T; Kato, M; Koida, M, 1996) |
| "Decreased body weight was observed in mice treated with 5-FU and UFT but not in those treated with S-1." | 1.29 | [Immunotoxic effects of a new antineoplastic agent S-1 in mice--comparison with S-1, UFT and 5-FU]. ( Kouchi, Y; Maeda, Y; Morinaga, H; Ohuchida, A, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.00) | 18.7374 |
| 1990's | 10 (50.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 3 (15.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yong, T | 1 |
| Li, D | 1 |
| Li, M | 1 |
| Liang, D | 1 |
| Diao, X | 1 |
| Deng, C | 1 |
| Chen, S | 1 |
| Xie, Y | 1 |
| Chen, D | 1 |
| Zuo, D | 1 |
| Aoyama, T | 1 |
| Kawabe, T | 1 |
| Fujikawa, H | 1 |
| Hayashi, T | 6 |
| Yamada, T | 1 |
| Tsuchida, K | 1 |
| Yukawa, N | 1 |
| Oshima, T | 1 |
| Rino, Y | 1 |
| Masuda, M | 1 |
| Ogata, T | 1 |
| Cho, H | 1 |
| Yoshikawa, T | 1 |
| Li, H | 1 |
| Zhao, M | 1 |
| Su, G | 1 |
| Lin, L | 1 |
| Wang, Y | 1 |
| Sánchez-Lozada, LG | 1 |
| Soto, V | 1 |
| Tapia, E | 1 |
| Avila-Casado, C | 1 |
| Sautin, YY | 1 |
| Nakagawa, T | 1 |
| Franco, M | 1 |
| Rodríguez-Iturbe, B | 1 |
| Johnson, RJ | 1 |
| Mori, T | 1 |
| Fujiwara, Y | 1 |
| Yano, M | 1 |
| Tamura, S | 1 |
| Yasuda, T | 1 |
| Takiguchi, S | 1 |
| Monden, M | 1 |
| Yurimoto, S | 1 |
| Miyakawa, A | 1 |
| Okuzawa, A | 1 |
| Sakamoto, S | 1 |
| Sakamoto, K | 1 |
| Hosoda, S | 1 |
| Kamano, T | 1 |
| Moriyama, K | 1 |
| Kouchi, Y | 2 |
| Morinaga, H | 2 |
| Irimura, K | 2 |
| Ohuchida, A | 2 |
| Goto, T | 1 |
| Yoshizawa, Y | 1 |
| Tanaka, G | 3 |
| Hirota, T | 2 |
| Ohmae, S | 3 |
| Hasegawa, H | 1 |
| Hakoi, K | 1 |
| Besshi, K | 1 |
| Yamaguchi, S | 3 |
| Kito, S | 1 |
| Kurokawa, K | 1 |
| Kitajima, S | 1 |
| Okamura, T | 1 |
| Kobayashi, K | 1 |
| Watari, N | 1 |
| Inoue, H | 1 |
| Enomoto, M | 1 |
| Shinomiya, M | 3 |
| Imamura, K | 1 |
| Izumi, K | 1 |
| Yukiyama, S | 2 |
| Ikebuchi, K | 2 |
| Sato, T | 1 |
| Furuhashi, T | 1 |
| Kato, M | 1 |
| Fujimura, T | 1 |
| Koida, M | 1 |
| Maeda, Y | 1 |
| Kitamura, M | 1 |
| Arai, K | 1 |
| Iwasaki, Y | 1 |
| Takahashi, T | 1 |
| Saitoh, K | 1 |
| Fujii, T | 1 |
| Shirasaka, T | 1 |
| Yoshisue, K | 1 |
| Hironaga, K | 1 |
| Yamamoto, A | 1 |
| Nagayama, S | 1 |
| Kawaguchi, Y | 1 |
| Miyoshi, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors[NCT02454062] | Phase 1 | 120 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
20 other studies available for oxonic acid and Body Weight
| Article | Year |
|---|---|
Anti-Hyperuricemic Effect of 2-Hydroxy-4-methoxy-benzophenone-5-sulfonic Acid in Hyperuricemic Mice through XOD.
Topics: Animals; Benzophenones; Body Weight; Gene Expression Regulation; Glucose Transport Proteins, Facilit | 2018 |
Loss of Lean Body Mass as an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Composition; B | 2015 |
Effect of Soy Sauce on Serum Uric Acid Levels in Hyperuricemic Rats and Identification of Flazin as a Potent Xanthine Oxidase Inhibitor.
Topics: Animals; Body Weight; Carbolines; Drug Evaluation, Preclinical; Enzyme Inhibitors; Furans; Hyperuric | 2016 |
Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia.
Topics: Aldehydes; Angiotensin II; Animals; Antioxidants; Arterioles; Body Weight; Cyclic N-Oxides; Disease | 2008 |
Experimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Disease Models, Animal; Drug Combinations; Ea | 2003 |
Enhancement of the anti-tumor activity of S-1 by low-dose cisplatin in mice bearing the sarcoma-180 model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cisplatin; Drug Combinations; | 2005 |
Diamine oxidase, a plasma biomarker in rats to GI tract toxicity of oral fluorouracil anti-cancer drugs.
Topics: Administration, Oral; Amine Oxidase (Copper-Containing); Animals; Antimetabolites, Antineoplastic; A | 2006 |
[Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo].
Topics: Administration, Oral; Alopecia; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 1996 |
[A 13-week oral repeated dose toxicity study of a new antineoplastic agent S-1 in rats].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 1996 |
[A 26-week oral repeated dose toxicity study of a new antineoplastic agent S-1 in rats].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Blood Chemical Analysis; Body Weight | 1996 |
[An oral repeated dose toxicity study of a new antineoplastic agent S-1 in dogs. I. A 13-week repeated dose toxicity study. II. An ophthalmologic toxicity recovery study].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 1996 |
[A 52-week oral toxicity study of a new antineoplastic agent S-1 in dogs].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Blood Chemical Analysis; Blood Coagu | 1996 |
[Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (I)--Fertility study in rats by oral administration].
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Antimetabolites, Antineoplastic; Body We | 1996 |
[Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (II)--Teratological study in rats by oral administration].
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Animals, Newborn; Antimetabolites, Antin | 1996 |
[Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (IV)--Perinatal and postnatal study in rats by oral administration].
Topics: Administration, Oral; Animals; Animals, Newborn; Antimetabolites, Antineoplastic; Behavior, Animal; | 1996 |
[Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (III)--Teratological study in rabbits by oral administration].
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Antimetabolites, Antineoplastic; Body We | 1996 |
[Immunotoxic effects of a new antineoplastic agent S-1 in mice--comparison with S-1, UFT and 5-FU].
Topics: Animals; Antibody Formation; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1996 |
[Combined effect of S-1 and CDDP as a modulator for colon 26 liver metastasis].
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Cisplatin; Colonic Neoplasms; Drug Combinatio | 2000 |
Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Colon; Diarrhea; Digestive System; Drug Combi | 2000 |
[Study on mechanism of urate stone formation. I. Light microscopic study (author's transl)].
Topics: Animals; Body Weight; Kidney; Kidney Calculi; Kidney Tubules; Male; Oxonic Acid; Rats; Uric Acid | 1978 |